The high failure rate of drugs in human trials after passing animal tests stems from a fundamental biological reality: a "mouse is not a small human." This "structural mismatch" is especially severe for modern, human-specific therapies like CAR-T and RNA, rendering animal models poor proxies.

The platform achieves precision through a two-step process. First, focused ultrasound targets a specific organ for delivery. Second, the genetic payload itself contains regulatory elements like cell-specific promoters. This ensures that even though many cell types within the organ receive the payload, the therapeutic protein is only expressed in the desired cells.

Current drug development heavily relies on animal testing. However, significant biological differences mean we may be filtering out effective human medicines that fail in animal models, creating a hidden opportunity cost for medical breakthroughs.

Unlike viral vectors that depend on biological interactions, Sonothera's ultrasound delivery is payload-agnostic. By using physical force to create temporary cell pores, it can deliver DNA, RNA, or CRISPR systems without redesigning the therapeutic itself. This fundamentally decouples the genetic cargo from the delivery mechanism, offering unprecedented flexibility.

Histosonics is pioneering the next stage of surgery by using focused sound waves to non-invasively liquefy tumors. This breakthrough technology can treat patients previously deemed non-surgical candidates, improving their condition enough to make them eligible for surgical resection or even organ transplants, creating entirely new therapeutic pathways.

Sonothera's method physically deposits genetic payloads into cells through transient pores, bypassing the endosomal pathways used by viruses and LNPs. This avoids triggering innate immune sensors like CGAS and STING. This “immune stealth” approach is key to the platform's favorable safety profile and its ability to be repeatedly administered.

To bridge the gap between animal models and human trials, Noetik trains models on its human data and then runs inference on mouse histology (H&E) images. This allows them to predict human-relevant biology and gene expression directly from the mouse model, overcoming a key translational hurdle in drug development.

Before targeting difficult tissues, Sonothera first focused on liver delivery of Factor VIII. This allowed them to directly compare their platform's safety and efficacy against established AAV and LNP benchmarks in a well-understood context. This strategic move built credibility and de-risked the technology before pursuing more novel applications.

Unlike using genetically identical mice, Gordian tests therapies in large, genetically varied animals. This variation mimics human patient diversity, helping identify drugs that are effective across different biological profiles and addressing patient heterogeneity, a primary cause of clinical trial failure.